news

Zhao Yeqing, case filed

2024-08-17

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina


[Introduction] Jincheng Pharmaceutical's actual controller and chairman Zhao Yeqing was filed by the China Securities Regulatory Commission

China Fund News reporter Yishan

On August 16, Jincheng Pharmaceutical issued an announcement stating thatThe company's actual controller and chairman, Zhao Yeqing, was filed by the China Securities Regulatory Commission for suspected manipulation of the securities market

Suspected of manipulating the securities market

The announcement shows that Zhao Yeqing received a "Notice of Case Filing" issued by the China Securities Regulatory Commission on August 14. Due to suspected illegal and irregular behavior of manipulating the securities market, the China Securities Regulatory Commission decided to file a case against Zhao Yeqing in accordance with the Securities Law of the People's Republic of China, the Administrative Penalty Law of the People's Republic of China and other laws and regulations.


According to the 2023 annual report, Zhao Yeqing was born in 1976 and holds a doctorate in business administration. Since July 2004, Zhao Yeqing has served as assistant general manager, executive deputy general manager, and director of Shandong Jincheng Pharmaceutical Chemical Co., Ltd. He is currently the chairman of Jincheng Pharmaceutical, chairman of Jincheng Pharmaceutical Research Institute, director of Jincheng Industrial and Jincheng Jinsu, executive director of Jincheng Taier and Jincheng Fanglue, and director of Dongfanglue.

Jincheng Pharmaceutical stated that the case investigation is an investigation into personal behavior, and the company will continue to pay attention to the progress of the above matters and strictly fulfill its information disclosure obligations in accordance with regulatory requirements. As of the date of disclosure of this announcement, the company's production and operation are normal.

According to the official website, the 20th anniversary celebration and high-quality development conference of Jincheng Pharmaceutical Group was held at Zibo Convention and Exhibition Center on August 8. At the conference, Zhao Yeqing, Party Secretary and Chairman of Jincheng Pharmaceutical Group, said that in the future, the company will adhere to the overall strategy of "focusing on the main business, aggregating resources, and focusing on innovation", and strive to become an "innovative leading enterprise in the pharmaceutical and health industry".

The stock price has fallen by more than 13% this year.

According to data, Jincheng Pharmaceutical was established in 2004 and listed on the Growth Enterprise Market in June 2011. The company is mainly engaged in the research and development, production and sales of pharmaceutical intermediates, APIs, pharmaceutical preparations, health products, synthetic biology products, as well as pharmaceutical intermediates and API CMO/CDMO services, with three preparation production bases in Beijing, Guangdong and Shanghai.

In the first quarter of this year, the company achieved revenue of 932 million yuan, a year-on-year increase of 12.32%; net profit attributable to the parent company was 82.9713 million yuan, a year-on-year increase of 65.43%. As of August 9, the company had 28,300 shareholders.


As of the close of August 16, Jincheng Pharmaceutical was trading at 14.38 yuan per share, down more than 13% this year, with a latest market value of 5.5 billion yuan.


Editor: Captain

Review: Xu Wen

Copyright Notice

"China Fund News" enjoys the copyright to the original content published on this platform. Reproduction without authorization is prohibited, otherwise legal liability will be pursued.

Contact person for authorized reprint cooperation: Mr. Yu (Tel: 0755-82468670)